At the 2026 Peking University Diabetes Forum, Chipscreen Biosciences and JD Health jointly launched the “White Paper on the Current Status and Future of Comprehensive Insulin Resistance Management in China (2025)”. Drawing on insights from internet hospital clinical practices, physician surveys, patient questionnaires, and evidence-based medical research, the “White Paper” provides the first systematic review of the disease burden, current awareness, and comprehensive management pathways for insulin resistance in China. It proposes a management approach centered on “early screening, early diagnosis, and comprehensive intervention,” with the goal of advancing chronic disease management in China beyond glycemic control alone toward comprehensive metabolic management.